HEALTH OF WOMAN. 2016.9(115):103–111; doi 10.15574/HW.2016.115.103 
 

Рак грудной железы в репродуктивном возрасте, индукторы риска и роль витамина D 
 

Веропотвелян П. Н., Цехмистренко И. С., Веропотвелян Н. П., Яручик С. П., Степанович И. В.

ОКУ «Межобластной центр медицинской генетики и пренатальной диагностики», г. Кривой Рог

Перинатальный центр, г. Киев

КУ «Криворожский онкологический диспансер» ДОС» 
 

В статье представлены индукторы риска развития рака грудных желез (РГЖ).

Принимая во внимание риски развития РГЖ у женщин в разные возрастные периоды, целесообразно применение таргетной онкопротективной и симптоматической терапии. Полиморфизм гена витамина D, различная экспрессия ферментов, участвующих в синтезе биологически активной формы витамина D и катаболизме витамина, в конечном счете определяют локальную концентрацию витамина D. Последний регулирует пролиферацию клеток грудной железы, которая является предиктором доброкачественных поражений и онкопатологии грудной железы. Своевременная коррекция дефицита витамина D является одним из эффективных методов первичной профилактики РГЖ.

Ключевые слова: рак грудной железы, индукторы риска, витамин D, рецепторы витамина D, полиморфизм гена витамина D, мастодиния, 
дисгормональные заболевания грудной железы.

Литература: 
1. Clinical Effectiveness Unit. Contraception for women aged 40 years. London (England): Faculty of Sexual and Reproductive Healthcare (FSRH). 2010; Jul. 26 p.

2. Thorbjarnardottir T. Oral contraceptives, hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older /E.J. Olafsdottir, U.A. Valdimarsdottir, O. Olafsson, L. Tryggvadottir // Acta Oncol. 2014; 53: 752-8. https://doi.org/10.3109/0284186X.2013.878471 ; PMid:24460068

3. Wilson A.R. EUSOMA (European Society of Breast Cancer Specialists). The requirements of a specialist Breast Centre /L. Marotti, S. Bianchi, L. Biganzoli, S. Claassen, T. Decker T. et al. //Eur. J. Cancer. 2013; 49(17): 3579-87.

4. Fiuza-Luces C. Exercise is the real polypill /N. Garatachea, N.A. Berger, A. Lucia //Physiology (Bethesda). 2013; 28(5): 330-58. https://doi.org/10.1152/physiol.00019.2013

5. Yamamoto N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF) /H. Suyama, N. Yamamoto, N. Ushijima //Int. J. Cancer. 2008; 122(2): 461-7.

6. Dragoslava Zivadinovic. Membrane estrogen receptor- alpha levels predict estrogeninduced ERK Ѕ activation in MCF-7 cells /S. Watson Cheryl //Breast Cancer Res. 2005; 7:130-114. https://doi.org/10.1186/bcr959; PMid:15642162 PMCid:PMC1064105

7. Смоланка И.И. Взгляд онколога на репродуктивное здоровье женщины //З турботою про жінку. 2016; 4(70): 11-12.

8. Radzinsky V.E. The possibility of a combination therapy of uterine fibroids and benign mammary dysplasia /I.M. Ordiyants, M.N. Maslennikov, E.A. Pavlova, V.V. Kardanova //Obstetrics and Gynecology. 2013; 4: 44-47.

9. Chung J.G. Effects of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) on the acetylation of 2-aminofluorene and DNA-2-aminofluorene adducts in the rat. Toxicol Sci. 1999; 51(2): 202-10. https://doi.org/10.1093/toxsci/51.2.202; PMid:10543022

10. Maltsevа L.I. Vitamin D and breast cancer in women gland /Y. Haryfullova // Obstetrics and Gynaecology. 2015; 8: 33-38.

11. Novikovа V.A. Factors line breast cancer glands in the reproductive age //Obstetrics and Gynaecology. 2015;10: 27-34.

12. Socolov D. Benign breast disease and the risk of breast cancer in the next 15 years /І. Anghelache, С. Ilea, R. Socolov, A. Carauleanu //Rev. Med. Chir. Soc. Med. Nat. Iasi. 2015; 119(1): 135-40.

13. Dyrstad S.W. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis /Y. Haryfullova //Breast Cancer Res. Treat. 2015; 149(3): 569-75.

14. Gradishar W.J. Breast Cancer Version 2.2015 /B.O. Anderson, R. Balassanian, S.L. Blair, H.J. Burstein, A. Cyr et al. //J. Natl. Compr. Canc. Netw. 2015; 13(4): 448-75.

15. Bellcross C. Approaches to applying breast cancer risk prediction models in clinical practice //Commun. Oncol. 2009; 6(8): 373-82.

16. Емец Н.А. Роль прогестерона в терапии дисгормональных заболеваний МЖ. От теории к практическому применению //З турботою про жінку. 2016; 5(71): 16-17.

17. Boonyaratanakornkit V. The role of ovarian sex steroids in metabolic homeostasis, obesity, and postmenopausal breast cancer: molecular mechanisms and therapeutic implications /P. Pateetin //Biomed. Res. Int. 2015; 2015: Article ID 140196.

18. Brisken C. Hormone action in the mammary gland /B. O’Malley //Cold Spring Harb. Perspect. Biol. 2010; 2(12): a003178.

19. Xie M. Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells /L. Zhou, X. Chen, L.O. Gainey, J. Xiao, M.S. Nanes et al. //Biomed. Res. Int. 2015; 2015: Article ID 426429.

20. Melander O. Stable peptide of the endogenous opioid enkephalin precursor and breast cancer risk /M. Orho-Melander, J. Manjer, Th. Svensson, P. Almgren, P.M. Nilsson et al //J. Clin. Oncol. 2015; 33(24): 2632-8.

21. Joung K.H. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms /J.- W. Jeong, B. J. Ku //Biomed. Res. Int. 2015; 2015: Article ID 920618.

22. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press; 2010.

23. Bischoff-Ferrari H.A. Vitamin D deficiency: evidence, safety, and recommendations for the Swiss population /P. Burckhardt, K. Quack-Loetscher, B. Gerber, D. I’Allemand, J. Laimbacher, M. Bachmann, R. Rizzoli /Report written by a group of experts on behalf of the Federal Commission for Nutrition (FCN). 2012. Available at: http: //www. iccidd. org/ p142000804. html. 3.

24. Dawson-Hughes B. IOF position statement: vitamin D recommendations for older adults /A. Mithal, J.P. Bonjour, S. Boonen, P. Burckhardt, G.E. Fuleihan et al. //Osteoporos. Int. 2010; 21(7): 1151-4. https://doi.org/10.1007/s00198-010-1285-3

25. Elamin M.B. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis /Abu Elnour N.O., Elamin K.B., Fatourechi M.M., Alkatib A.A., Almandoz J.P. et al. //J. Clin. Endocrinol. Metab. 2011; 96 (7): 1931-42. https://doi.org/10.1210/jc.2011-0398; PMid:21677037

26. Mitri J. Vitamin D and diabetes /A.G. Pittas //Endocrinol. Metab. Clin. North Am. 2014; 43(1): 205-32. https://doi.org/10.1016/j.ecl.2013.09.010; PMid:24582099 PMCid:PMC3942667

27. Ooi L.L. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis /H. Zhou, R. Kalak, Y. Zheng, A.D. Conigrave, M.J. Seibel, C.R. Dunstan //Cancer Res. 2010; 70(5): 1835-44. https://doi.org/10.1158/0008-5472.CAN-09-3194; PMid:20160035

28. Garland C. Epidemiology of cancer risk and vitamin D. In: Holick M., ed. Vitamin D: molecular biology, physiology, and applications / Garland F., Gorham E. //Totowa, New Jersey: Humana Press; 1999: 375-409.

29. John E.M.Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey /G.G. Schwartz, D.M. Dreon, J. Koo //Cancer Epidemiol. Biomarkers Prev. 1999; 8(5): 399-406. PMid:10350434

30. Gorham E.D. Acid haze air pollution and breast and colon cancer in 20 Canadian cities /C.F. Garland, F.C. Garland //Can. J. Public Health. 1989; 80(2): 96-100. PMid:2720547

31. Garland C.F. Vitamin D and prevention of breast cancer: pooled analysis /E.D. Gorham, S.B. Mohr, W.B. Grant, E.L. Giovannucci, M. Lipkin et al. // J. Steroid Biochem. Mol. Biol. 2007; 103(3-5): 708-11. https://doi.org/10.1016/j.jsbmb.2006.12.007; PMid:17368188

32. Rejnmark L. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study /A. Tietze, P. Vestergaard, L. Buhl, M. Lehbrink, L. Heickendorff, L. Mosekilde //Cancer Epidemiol. Biomarkers Prev. 2009; 18(10): 2655-60. https://doi.org/10.1158/1055-9965.EPI-09-0531; PMid:19789365

33. Toner C.D. The vitamin D and cancer conundrum: aiming at a moving target /C.D. Davis, A. John, J.A. Milner //J. Am. Diet. Assoc. 2010; 110(10): 1492-500. https://doi.org/10.1016/j.jada.2010.07.007; PMid:20869488

34. Goodwin P.J. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer /M. Ennis, K.I. Pritchard, J. Koo, N. Hood //J. Clin. Oncol. 2009; 27(23): 3757-63. https://doi.org/10.1200/JCO.2008.20.0725; PMid:19451439

35. Colston K.W. Vitamin D and breast cancer risk. Best Pract. Res. //Clin. Endocrinol. Metab. 2008; 22(4): 587-99.

36. Zinser G.M. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues /M. Suckow, J. Welsh //J. Steroid Biochem. Mol. Biol. 2005; 97(1-2): 153-64. https://doi.org/10.1016/j.jsbmb.2005.06.024; PMid:16111884

37. McCullough M.L. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer /R.M. Bostick, T.L. Mayo //Annu. Rev. Nutr. 2009; 29: 111-32. https://doi.org/10.1146/annurev-nutr-080508-141248; PMid:19400699

38. Raimondi S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk /H. Johansson, P. Maisonneuve, S. Gandini //Carcinogenesis. 2009; 30(7): 1170-80. https://doi.org/10.1093/carcin/bgp103; PMid:19403841

39. Tang C. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis /N. Chen, M. Wu, H. Yuan, Y. Du //Breast Cancer Res. Treat. 2009; 117(2): 391-9. https://doi.org/10.1007/s10549-008-0262-4; PMid:19145484

40. Colin E.M. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3 /A.E. Weel, A.G. Uitterlinden, C.J. Buurman, J.C. Birkenhдger, H.A. Pols, J.P. van Leeuwen //Clin. Endocrinol. (Oxford). 2000; 52(2): 211-6. https://doi.org/10.1046/j.1365-2265.2000.00909.x

41. Uitterlinden A.G. Genetics and biology of vitamin D receptor polymorphisms /Y. Fang, J.B. Van Meurs, H.A. Pols, J.P. Van Leeuwen //Gene. 2004; 338(2): 143-56. https://doi.org/10.1016/j.gene.2004.05.014; PMid:15315818

42. Mehta R.G. Vitamin D and breast cancer: emerging concepts /X. Peng, F. Alimirah, G. Murillo, R. Mehta //Cancer Lett. 2013; 334(1): 95-100. https://doi.org/10.1016/j.canlet.2012.10.034; PMid:23142286

43. Dalessandri K.M. Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study /R. Miike, J.K. Wiencke, G. Farren, T.W. Pugh, S. Manjeshwar et al. //J. Am. Coll. Surg. 2012; 215(5): 652-7. https://doi.org/10.1016/j.jamcollsurg.2012.06.413; PMid:22867716

44. Lundin A.C. South-East Sweden Breast Cancer Group. Association of breast cancer progression with a vitamin D receptor gene polymorphism /P. Soderkvist, B. Eriksson, M. Bergman-Jungestrom, S. Wingren //Cancer Res. 1999; 59(10): 2332-4. PMid:10344739

45. Lowe L.C. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotypes and breast cancer risk in a UK Caucasian population /M. Guy, J.L. Mansi, C. Peckitt, J. Bliss, R.G. Wilson, K.W. Colston //Eur. J. Cancer. 2005; 41(8): 1164-9. https://doi.org/10.1016/j.ejca.2005.01.017; PMid:15911240

46. Lopes N. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions /B. Sousa, D. Martins, M. Gomes, D. Vieira, L.A. Veronese et al. //BMC Cancer. 2010; 10: 483. Available at: http://www.biomedcentral.com/1471-2407/10/483. https://doi.org/10.1186/1471-2407-10-483; PMid:20831823 PMCid:PMC2945944

47. Hereditary Breast and/or Ovarian Cancer Syndrome. NCCN Guidelines Version 4.2013.Available at: http://www.nccn.org/professionals/physician_gls/pdf

/genetics_screening.pdf. Accessed October 30, 2013.

48. Lanfranchi A.E. Breast cancer and induced abortion: a comprehensive review of breast development and pathophysiology, the epidemiologic literature, and proposal for creation of databanks to elucidate all breast cancer risk factors /P. Fagan // Issues Law Med. 2014 Spring; 29(1): 3-133. PMid:25189012

49. Radzinsky V.E. Breast and gynecological disease /I.M. Ordiyants, L.K. Hasanova, L.R. Toktar, V.I. Zubkin //Moscow; 2010; 304p.

50. Del Prete A. Molecular pathways in cancer-related inflammation /P. Allavena, G. Santoro, R. Fumarulo, M.M. Corsi, A. Mantovani //Biochem. Med. (Zagreb). 2011; 21(3): 264-75. https://doi.org/10.11613/BM.2011.036

51. Rouzvia S.K. Gynecology . Almost Directory doctor. Per. with English. Ailamazyan EK , ed. M .: MEDpress -inform ; 2004; 519.

52. Fei Ch. Fertility drugs and young-onset breast cancer: results from the Two Sister Study /L.A. DeRoo, D.P. Sandler, C.R. Weinberg //J. Natl. Cancer Inst. 2012; 104(13): 1021-7. https://doi.org/10.1093/jnci/djs255; PMid:22773825 PMCid:PMC3634553

53. Scoccia B. O-064 Long-term relationship of ovulation-stimulating drugs to breast and gynecologic cancers. In: Abstracts of the 30th Annual Meeting of the European Society of Human Reproduction and Embryology. 29 June — 2 July 2014 Munich, Germany / K. Moghissi, C. Westhoff, S. Niwa, D. Ruggieri, B. Trabert et al. //Hum. Reprod. 2014; 29(Suppl.1): i27.

54. Tanday S. Fertility drugs not linked to cancer risk //Lancet. Oncol. 2014; 15(9): 367. doi: http: //dx. doi. org/10. 1016/S1470-2045(14)70300-6

55. Podzolkova N.M. AL Eye Obesity and Function reproduktyvnaya women /I.V. Kuznetsov //Uchebnoe posobye . M .;2006; 28.

56. Khawaja A. Thompson Ch.L. Sleep duration and breast cancer phenotype /S. Rao, L. Li //J. Cancer Epidemiol. 2013; 2013: Article ID 467927. https://doi.org/10.1155/2013/467927; PMid:24319459 PMCid:PMC3834985

57. Haider M.H. Iatrogenic arteriovenous fistula of the breast as a complication of core needle biopsy /A. Satpathy, W. Abou-Samra //Ann. R. Coll. Surg. Engl. 2014; 96(8): e20-2. https://doi.org/10.1308/003588414X13946184903162; PMid:25350171 PMCid:PMC4474130

58. Manshadi Deghan S. Folic acid supplementation promotes mammary tumor progression in a rat model /L. Ishiguro, K.-J. Sohn, A. Medline, R. Renlund, R. Croxford, Y.I. Kim //PLoS One. 2014; 9(1): 84635. https://doi.org/10.1371/journal.pone.0084635; PMid:24465421 PMCid:PMC3897399

59. Beaber E.F. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age /D.S.M. Buist, W.E. Barlow, K.E. Malone, S.D. Reed, C.I. //Cancer Res. 2014; 74(15): 4078–89. https://doi.org/10.1158/0008-5472.CAN-13-3400; PMid:25085875 PMCid:PMC4154499

60. Gierisch J.M. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review /R.R. Coeytaux, R. Peragallo Urrutia, L.J. Havrilesky, P.G. Moorman, W.J. Lowery et al. //Cancer Epidemiol. Biomarkers Prev. 2013; 22(11): 1931–43. https://doi.org/10.1158/1055-9965.EPI-13-0298; PMid:24014598

61. Hou N. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density /S. Hong, W. Wang, O.I. Olopade, J.J. Dignam, D. Huo //J. Natl. Cancer Inst. 2013; 105(18): 1365–72. https://doi.org/10.1093/jnci/djt207; PMid:24003037 PMCid:PMC3776262

62. http: // onkolog-24.ru/rak-molochnoy-zhelezy-u-zhenshchin.html

63. Okulov A.B. Hypospadias and gynecomastia markers of disorders sex differentiation /D.N. Brovin, E.A. Volodko //Attending physician. 2005; 7: 28–32.

64. Schwartz G.Y. vitamin D Deficiency and its pharmacological correction. Regular issues of «BC» No. 7 dated 06.04.2009 page 477.

65. Kochetkova E.A. Cancer risk breast and ovarian cancer caused by mutations of genes BRCA1, BRCA2, CHEK2 /N.To. Degenertive //Kazakhstan Medical Journal 2013; 4(34) July-August.